Ulixertinib is under clinical development by BioMed Valley Discoveries and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ulixertinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ulixertinib (BVD-523) is under development for the treatment of metastatic uveal melanoma, metastatic melanoma, non-small cell lung cancer, acute myelogenous leukemia, metastatic colorectal cancer, metastatic pancreatic cancer, myelodysplastic syndromes, esophageal squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, gastric cancer, pancreatic cancer, extrahepatic bile duct cancer, low grade glioma, oligodendroglioma, neurofibromatosis type 1 and bile duct cancer . The drug candidate is a small molecule and is administered orally. It acts by targeting ERK1 and 2 (Extracellular signal-Regulated Kinases).
It was also under development for metastatic adenocarcinoma of the pancreas.
BioMed Valley Discoveries overview
BioMed Valley Discoveries (BioMed) a subsidiary of Stowers Institute for Medical Research is a clinical stage biotechnology company which develops novel medicines for cancer. The company’s product portfolio includes CNV-NT an injection of clostridium novyi-NT spores to treat solid tumors, BVD-523 for the treatment of metastatic pancreatic cancer. It also provides BVD-723, a gamma inhibitor which counteracts cancer’s evasiveness and help boost an immune response to the disease, CD276 antibody-drug conjugate (ADC) used as a therapeutic agent to target multiple solid tumor. The company is developing therapies in the areas of oncology and immuno-oncology. BioMed is headquatered in Kansas, ?Missouri, the US.
For a complete picture of Ulixertinib’s drug-specific PTSR and LoA scores, buy the report here.